Inhibikase Therapeutics (IKT) Enterprise Value (2020 - 2025)
Inhibikase Therapeutics (IKT) has disclosed Enterprise Value for 6 consecutive years, with -$77.3 million as the latest value for Q3 2025.
- Quarterly Enterprise Value fell 2283.81% to -$77.3 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was -$77.3 million through Sep 2025, down 2283.81% year-over-year, with the annual reading at -$138.6 million for FY2024, 945.52% down from the prior year.
- Enterprise Value for Q3 2025 was -$77.3 million at Inhibikase Therapeutics, up from -$87.7 million in the prior quarter.
- The five-year high for Enterprise Value was -$3.2 million in Q3 2024, with the low at -$138.6 million in Q4 2024.
- Average Enterprise Value over 5 years is -$39.7 million, with a median of -$26.5 million recorded in 2022.
- The sharpest move saw Enterprise Value crashed 601525.64% in 2021, then skyrocketed 80.73% in 2024.
- Over 5 years, Enterprise Value stood at -$40.8 million in 2021, then surged by 43.44% to -$23.1 million in 2022, then skyrocketed by 42.51% to -$13.3 million in 2023, then crashed by 945.52% to -$138.6 million in 2024, then soared by 44.19% to -$77.3 million in 2025.
- According to Business Quant data, Enterprise Value over the past three periods came in at -$77.3 million, -$87.7 million, and -$93.2 million for Q3 2025, Q2 2025, and Q1 2025 respectively.